DOJ Sues Major Drug Distributor Over Opioid Crisis Compliance Failures

The U.S. Department of Justice filed a civil lawsuit on January 14, 2025, against Morris & Dickson Co., LLC, a Louisiana-based wholesale drug distributor, alleging systematic failures to report and halt suspicious orders of opioids in violation of the Controlled Substances Act (CSA). The complaint marks the first major federal enforcement action against a distributor since the implementation of enhanced DEA suspicious order monitoring rules in October 2021.

Regulatory Background

Under 21 U.S.C. § 823(e) and 21 CFR § 1301.74(b), wholesale drug distributors holding DEA registration must design and operate an effective system to detect, investigate, and report suspicious orders of controlled substances. The CSA defines a suspicious order as one of unusual size, unusual frequency, or that deviates substantially from a normal pattern. Distributors are required to:

1. Halt shipment of any order they determine to be suspicious
2. Conduct due diligence to determine whether the order is legitimate
3. Report suspicious orders to the DEA within one business day using DEA Form 333

The DEA's updated guidance (DEA-DC-018, October 2021) clarified that distributors must establish customer-specific and product-specific thresholds based on historical ordering patterns, geographical market factors, and available prescription data. Distributors cannot rely solely on DEA quota allocations as evidence that an order is legitimate.

Details of the Complaint

The DOJ complaint alleges that Morris & Dickson distributed more than 100 million dosage units of oxycodone and hydrocodone to pharmacies in Louisiana, Mississippi, and Alabama between 2014 and 2021, despite red flags indicating potential diversion. Specific allegations include:

• Failure to implement order monitoring thresholds: The company allegedly continued shipping orders that exceeded established size and frequency limits without adequate investigation.
• Inadequate due diligence procedures: Internal compliance staff allegedly lacked authority to halt shipments even when suspicious activity was identified.
• Non-reporting of suspicious orders: The complaint cites fewer than 20 suspicious order reports filed during a six-year period when DEA estimates the company should have reported hundreds of orders.
• Ignoring pharmacy dispensing patterns: The distributor allegedly shipped opioids to pharmacies in jurisdictions with abnormally high per-capita opioid consumption rates without adjusting thresholds or conducting enhanced due diligence.

The DOJ is seeking civil monetary penalties under 21 U.S.C. § 842(c)(1)(A), which allows fines up to $10,000 per violation. With allegations spanning thousands of shipments, potential penalties could exceed $100 million.

Impact on Wholesale Drug Distributors

This enforcement action clarifies DEA's expectations for suspicious order monitoring systems in three operational areas:

Threshold methodology: Distributors must document the basis for customer-specific order limits. Relying on generic percentile-based thresholds (e.g., "orders above the 95th percentile are flagged") is insufficient if those thresholds do not account for actual prescription market dynamics or patient population factors in a pharmacy's service area.

Compliance authority structure: Due diligence teams must have unilateral authority to halt shipments pending investigation. Business development or sales departments cannot override compliance holds.

Documentation requirements: Distributors must retain records of all flagged orders, investigation findings, and the rationale for either reporting or clearing the order. The DOJ complaint cites lack of documentation as evidence of systemic non-compliance, not isolated failures.

For 3PLs handling controlled substances on behalf of registered distributors, this case underscores that DEA distributor requirements apply regardless of inventory ownership structure. If the 3PL performs order fulfillment functions, it must operate within the registered distributor's suspicious order monitoring program and cannot ship flagged orders without compliance clearance.

What ColdChainCheck Data Shows

ColdChainCheck tracks 1,275 wholesale drug distributors and 3PLs across 51 jurisdictions. DEA registration data is not currently included in the compliance scoring methodology due to access limitations under the Ryan Haight Act data request process, but ColdChainCheck is monitoring public enforcement actions and state pharmacy board disciplinary records that may indicate controlled substance compliance failures.

The current compliance score distribution shows 919 entities (72%) in the "Fair" tier (40-59 points), meaning most tracked distributors have some verified compliance signals but lack full documentation across all six scoring dimensions. Only 28 entities (2%) achieve "Excellent" scores (80-100 points), reflecting complete NABP accreditation, multi-state licensure, and clean enforcement records. The 38 entities in the "Poor" tier (20-39 points) have minimal verified compliance signals—these are the highest-risk entities for due diligence teams to flag.

As of January 2025, 73 entities in the directory have at least one FDA recall or warning letter on record. While these enforcement actions primarily involve FDCA violations (temperature excursions, misbranding, cGMP failures) rather than CSA violations, they indicate compliance infrastructure weaknesses. Distributors with documented FDA enforcement history may warrant enhanced due diligence for controlled substance handling capabilities.

Practical Guidance for Trading Partner Qualification

For QA Managers conducting distributor assessments:

• Cross-reference license status in controlled substance states: Use the ColdChainCheck directory to verify active state pharmacy board licenses in jurisdictions where your facilities operate. State boards typically list DEA registration numbers on distributor license records, which can be independently verified against the DEA's public diversion control database.

• Request suspicious order monitoring documentation: During site audits or qualification questionnaires, require distributors to provide written policies for controlled substance threshold setting, due diligence procedures, and compliance department authority structures. Ask for examples of cleared vs. reported suspicious orders (redacted for confidentiality) to verify the system is operational, not theoretical.

• Monitor enforcement actions: ColdChainCheck tracks FDA warning letters and state pharmacy board disciplinary actions. A distributor with recent enforcement history for record-keeping failures or regulatory non-compliance may have systemic issues extending to controlled substance monitoring. Check the entity's compliance record in the directory before executing new trading partner agreements.

• Document DEA registration verification: While ColdChainCheck does not yet include DEA registration in the compliance score, distributors handling Schedule II-V substances must hold valid DEA Form 225 registration. Request a copy of the current registration certificate and verify the registration number matches state pharmacy board records. For comprehensive verification procedures, see the distributor license verification guide.

ColdChainCheck will continue tracking enforcement actions related to wholesale distributor compliance. For regulatory updates on DSCSA, FDA enforcement, and state pharmacy board actions, see the Compliance Guides section.

This article provides regulatory context for informational purposes only. It does not constitute legal advice. Distributors should consult with DEA counsel regarding specific compliance obligations under 21 U.S.C. § 823(e) and 21 CFR Part 1301.